Effect of the angiotensin receptor blocker valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease

Microcirculation

Volumn 14, Issue 8, 2007, Pages 805-812

  Higuchi, Takahiro ^a   Abletshauser, Claudia ^b   Nekolla, Stephan G ^a   Schwaiger, Markus ^a,c   Bengel, Frank M ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Novartis Pharma ^*  (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II type 1 receptor blocker; Cardiac PET; Coronary flow reserve; Hypertension; Valsartan

Indexed keywords

ADENOSINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLD PRESSOR TEST; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTENSION; MALE; MICROCIRCULATION; OUTCOME ASSESSMENT; PHARMACOLOGIC STRESS TESTING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR RESISTANCE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CORONARY ARTERY DISEASE; FEMALE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 36248948544     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1080/10739680701410827     Document Type: Article

References (39)

1. Burnier, M. (2001) Angiotensin II type 1 receptor blockers. Circulation, 103, pp. 904-912.
2. Lindholm, L. H., Ibsen, H., Dahlof, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J. and Snapinn, S. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, pp. 1004-1010.
3. Velazquez, E. J., Pfeffer, M. A., McMurray, J. V., Maggioni, A. P., Rouleau, J. L., Van de Werf, F., Kober, L., White, H. D., Swedberg, K., Leimberger, J. D., Gallo, P., Sellers, M. A., Edwards, S., Henis, M. and Califf, R. M. (2003) VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: Baseline characteristics in context. Eur J Heart Fail, 5, pp. 537-544.
4. Boos, C. (2004) Cardiovascular protection with ace inhibitors-more HOPE for EUROPA?. Med Sci Monit, 10, pp. SR23-SR28.
5. Kjeldsen, S. E. and Julius, S. (2004) Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J, 148, pp. 747-754.
6. Dahlof, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S. and Wedel, H. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, pp. 995-1003.
7. Wing, L. M., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., Morgan, T. O. and West, M. J. (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med, 348, pp. 583-592.
8. Pfeffer, M. A., McMurray, J. J., Velazquez, E. J., Rouleau, J. L., Kober, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., Leimberger, J. D., Henis, M., Edwards, S., Zelenkofske, S., Sellers, M. A. and Califf, R. M. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med, 349, pp. 1893-1906.
9. Lonn, E. (2002) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep, 4, pp. 363-372.
10. Schiffrin, E. L. (2002) Beyond blood pressure: The endothelium and atherosclerosis progression. Am J Hypertens, 15, pp. 115S-122S.
11. Lerman, A. (2005) Restenosis: Another "dysfunction" of the endothelium. Circulation, 111, pp. 8-10.
12. Suwaidi, J. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes Jr., D. R. and Lerman, A. (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 101, pp. 948-954.
13. Monnink, S. H., Tio, R. A., van Boven, A. J., van Gilst, W. H. and van Veldhuisen, D. J. (2004) The role of coronary endothelial function testing in patients suspected for angina pectoris. Int J Cardiol, 96, pp. 123-129.
14. Mancini, G. B., Henry, G. C., Macaya, C., O'Neill, B. J., Pucillo, A. L., Carere, R. G., Wargovich, T. J., Mudra, H., Luscher, T. F., Klibaner, M. I., Haber, H. E., Uprichard, A. C., Pepine, C. J. and Pitt, B. (1996) Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation, 94, pp. 258-265.
15. Sola, S., Mir, M. Q., Cheema, F. A., Khan-Merchant, N., Menon, R. G., Parthasarathy, S. and Khan, B. V. (2005) Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome. Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. Circulation, 25, pp. 343-348.
16. Hein, T. W., Belardinelli, L. and Kuo, L. (1999) Adenosine A(2A) receptors mediate coronary microvascular dilation to adenosine: Role of nitric oxide and ATP-sensitive potassium channels. J Pharmacol Exp Ther, 291, pp. 655-664.
17. Zeiher, A. M., Drexler, H., Wollschlaeger, H., Saurbier, B. and Just, H. (1989) Coronary vasomotion in response to sympathetic stimulation in humans: Importance of the functional integrity of the endothelium. J Am Coll Cardiol, 14, pp. 1181-1190.
18. Wilson, R. F., Wyche, K., Christensen, B. V., Zimmer, S. and Laxson, D. D. (1990) Effects of adenosine on human coronary arterial circulation. Circulation, 82, pp. 1595-1606.
19. Nekolla, S. G., Miethaner, C., Nguyen, N., Ziegler, S. I. and Schwaiger, M. (1998) Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med, 25, pp. 1313-1321.
20. Muzik, O., Beanlands, R., Wolfe, E., Hutchins, G. D. and Schwaiger, M. (1993) Automated region definition for cardiac nitrogen-13-ammonia PET imaging. J Nucl Med, 34, pp. 336-344.
21. Kanatsuka, H., Sekiguchi, N., Sato, K., Akai, K., Wang, Y., Komaru, T., Ashikawa, K. and Takishima, T. (1992) Microvascular sites and mechanisms responsible for reactive hyperemia in the coronary circulation of the beating canine heart. Circ Res, 71, pp. 912-922.
22. Kanatsuka, H., Lamping, K. G., Eastham, C. L., Dellsperger, K. C. and Marcus, M. L. (1989) Comparison of the effects of increased myocardial oxygen consumption and adenosine on the coronary microvascular resistance. Circ Res, 65, pp. 1296-1305.
23. Sato, A., Terata, K., Miura, H., Toyama, K., Loberiza Jr., F. R., Hatoum, O. A., Saito, T., Sakuma, I. and Gutterman, D. D. (2005) Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease. Am J Physiol Heart Circ Physiol, 288, pp. H1633-H1640.
24. Buus, N. H., Bottcher, M., Hermansen, F., Sander, M., Nielsen, T. T. and Mulvany, M. J. (2001) Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia. Circulation, 104, pp. 2305-2310.
25. Zeiher, A. M., Drexler, H., Wollschlager, H. and Just, H. (1991) Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation, 84, pp. 1984-1992.
26. Campisi, R., Czernin, J., Schoder, H., Sayre, J. W. and Schelbert, H. R. (1999) L-Arginine normalizes coronary vasomotion in long-term smokers. Circulation, 99, pp. 491-497.
27. Carli, M F Di, Tobes, M. C., Mangner, T., Levine, A. B., Muzik, O., Chakroborty, P. and Levine, T. B. (1997) Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med, 336, pp. 1208-1215.
28. Schindler, T. H., Nitzsche, E. U., Munzel, T., Olschewski, M., Brink, I., Jeserich, M., Mix, M., Buser, P. T., Pfisterer, M., Solzbach, U. and Just, H. (2003) Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: Contrasting myocardial blood flow responses to short- and long-term vitamin C administration. J Am Coll Cardiol, 42, pp. 814-822.
29. Ibrahim, T., Nekolla, S. G., Schreiber, K., Odaka, K., Volz, S., Mehilli, J., Guthlin, M., Delius, W. and Schwaiger, M. (2002) Assessment of coronary flow reserve: Comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography. J Am Coll Cardiol, 39, pp. 864-870.
30. Drzezga, A. E., Blasini, R., Ziegler, S. I., Bengel, F. M., Picker, W. and Schwaiger, M. (2000) Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl Med, 41, pp. 837-844.
31. Laine, H., Raitakari, O. T., Niinikoski, H., Pitkanen, O. P., Iida, H., Viikari, J., Nuutila, P. and Knuuti, J. (1998) Early impairment of coronary flow reserve in young men with borderline hypertension. J Am Coll Cardiol, 32, pp. 147-153.
32. Hamasaki, S., Suwaidi, J Al, Higano, S. T., Miyauchi, K., Holmes Jr., D. R. and Lerman, A. (2000) Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol, 35, pp. 1654-1660.
33. Nitenberg, A., Antony, I., Aptecar, E., Arnoult, F. and Lerebours, G. (1995) Impairment of flow-dependent coronary dilation in hypertensive patients. Demonstration by cold pressor test induced flow velocity increase. Am J Hypertens, 8, pp. 13S-18S.
34. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K. and Harrison, D. G. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest, 97, pp. 1916-1923.
35. Parodi, O., Neglia, D., Palombo, C., Sambuceti, G., Giorgetti, A., Marabotti, C., Gallopin, M., Simonetti, I. and L'Abbate, A. (1997) Comparative effects of enalapril and verapamil on myocardial blood flow in systemic hypertension. Circulation, 96, pp. 864-873.
36. Motz, W. and Strauer, B. E. (1996) Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension, 27, pp. 1031-1038.
37. Buus, N. H., Bottcher, M., Jorgensen, C. G., Christensen, K. L., Thygesen, K., Nielsen, T. T. and Mulvany, M. J. (2004) Myocardial perfusion during long-term angiotensin-converting enzyme inhibition or beta-blockade in patients with essential hypertension. Hypertension, 44, pp. 465-470.
38. Masuda, D., Nohara, R., Tamaki, N., Hosokawa, R., Inada, H., Hikai, T., Chen, L. G., Tadamura, E., Kudou, T., Konishi, J., Fujita, M. and Sasayama, S. (2000) Evaluation of coronary blood flow reserve by 13N-NH3 positron emission computed tomography (PET) with dipyridamole in the treatment of hypertension with the ACE inhibitor (Cilazapril). Ann Nucl Med, 14, pp. 353-360.
39. Schwartzkopff, B., Brehm, M., Mundhenke, M. and Strauer, B. E. (2000) Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension, 36, pp. 220-225.